Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STIM 
Neuronetics Inc (STIM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: STIM (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.83
1 Year Target Price $6.83
| 1 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 252.1% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 223.79M USD | Price to earnings Ratio - | 1Y Target Price 6.83 |
Price to earnings Ratio - | 1Y Target Price 6.83 | ||
Volume (30-day avg) 4 | Beta 1.92 | 52 Weeks Range 0.52 - 5.92 | Updated Date 07/4/2025 |
52 Weeks Range 0.52 - 5.92 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -54.23% | Operating Margin (TTM) -34.45% |
Management Effectiveness
Return on Assets (TTM) -19.39% | Return on Equity (TTM) -144.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 285901169 | Price to Sales(TTM) 2.5 |
Enterprise Value 285901169 | Price to Sales(TTM) 2.5 | ||
Enterprise Value to Revenue 3.2 | Enterprise Value to EBITDA -2.02 | Shares Outstanding 65820300 | Shares Floating 37163483 |
Shares Outstanding 65820300 | Shares Floating 37163483 | ||
Percent Insiders 9.17 | Percent Institutions 62.8 |
Upturn AI SWOT
Neuronetics Inc
Company Overview
History and Background
Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania. It is a commercial-stage medical device company focused on developing and marketing products that improve the quality of life for patients suffering from psychiatric disorders. The company's primary focus has been on developing and commercializing NeuroStar TMS Therapy system for treating Major Depressive Disorder (MDD).
Core Business Areas
- NeuroStar TMS Therapy Systems: Developing, manufacturing, and marketing NeuroStar TMS Therapy systems, used for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication. Revenue is generated from system sales, service contracts, and treatment sessions.
- Treatment Session Revenue: Generating revenue from treatment sessions administered on NeuroStar systems, either directly through Neuronetics-owned clinics or indirectly through usage-based agreements with partner clinics.
Leadership and Structure
Neuronetics is led by a board of directors and an executive leadership team. The CEO oversees the overall strategy and operations of the company. The organization is structured into departments such as sales, marketing, research and development, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- NeuroStar TMS Therapy System: The NeuroStar TMS Therapy System is the core product, delivering transcranial magnetic stimulation to treat MDD. Market share information is difficult to pinpoint, but the company competes in a market of TMS devices, with competitors like MagVenture, Brainsway, and CloudTMS. Market share data is estimated to be approximately 20-25% of the TMS market. Competitors include MagVenture, Brainsway, CloudTMS, and other TMS providers as well as alternative treatments such as ECT and medication.
Market Dynamics
Industry Overview
The industry Neuronetics operates in is the medical device sector, specifically focusing on neuromodulation for psychiatric disorders. The market is characterized by increasing awareness of mental health issues and a growing demand for non-pharmacological treatment options.
Positioning
Neuronetics is positioned as a leading provider of TMS therapy for MDD. Its competitive advantage lies in its established brand, clinical data supporting the efficacy of NeuroStar TMS, and a direct sales force.
Total Addressable Market (TAM)
The total addressable market for depression treatment, including TMS, is estimated to be in the billions of dollars. Neuronetics is positioned to capture a portion of this TAM by increasing awareness of TMS therapy and expanding its market reach.
Upturn SWOT Analysis
Strengths
- Established brand name (NeuroStar)
- Clinical data supporting efficacy
- Strong intellectual property portfolio
- Direct sales force
- FDA cleared
Weaknesses
- High cost of treatment
- Limited insurance coverage in some regions
- Dependence on a single core product
- Cash burn rate
- Profitability
Opportunities
- Expanding insurance coverage for TMS therapy
- Developing new applications for TMS technology
- International expansion
- Partnerships with mental health providers
- New technology for increased effectivity and efficiency
Threats
- Competition from other TMS providers
- Emergence of alternative treatments for MDD
- Changes in healthcare regulations
- Economic downturn affecting patient affordability
- Negative publicity regarding TMS therapy
Competitors and Market Share
Key Competitors
- MAGV
- BWAY
Competitive Landscape
Neuronetics faces competition from other TMS providers, pharmaceutical companies, and providers of alternative therapies. Its advantage lies in its brand recognition and clinical data. Its disadvantages include the high cost of treatment and dependence on a single core product.
Growth Trajectory and Initiatives
Historical Growth: Neuronetics' growth has been driven by increased adoption of TMS therapy. Specific growth rates require a review of historical revenue data.
Future Projections: Future growth projections are based on analyst estimates, which can be found on financial news websites. These projections depend on factors such as market adoption, reimbursement rates, and competition.
Recent Initiatives: Recent initiatives include expanding its sales force, improving insurance coverage, and developing new marketing campaigns.
Summary
Neuronetics, Inc. is a medical device company focused on TMS for MDD. The company has a solid brand and clinical data, but profitability remains a challenge. They face intense competition and must improve insurance coverage and expand their product pipeline. Overall, Neuronetics has potential but faces significant hurdles in achieving sustainable profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications.
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuronetics Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2018-06-28 | President, CEO & Director Mr. Keith J. Sullivan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 716 | Website https://neurostar.com |
Full time employees 716 | Website https://neurostar.com | ||
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.